AMD's stock has surged over 200% in the past year due to strong AI accelerator demand from major clients like OpenAI and Meta, with Q2 revenue up 50% and data center revenue doubling. Despite this growth, the stock trades at a high valuation with a trailing P/E of 194, raising concerns about execution risks and market conditions. Analysts set a 12-month price target slightly below current levels at $480.90, recommending a hold position while watching for potential pullbacks or further AI deployment progress. Risks include production yield issues and geopolitical factors like China export policies.
AMD's AI chip progress is notable amid a mixed Technology sector on Pluang. Of 150 priced US tech stocks, 66 rose and 82 fell as of Sep 15, 2026 23:03 WIB. Among movers, RIOT declined 4.77% to USD 19.95, FUBO dropped 4.55% to USD 11.33, and GPRO fell 4.44% to USD 1.29.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
